Novo Nordisk buyback program: Can NVO regain upward momentum?

Traders Union
All News
Stocks
Novo Nordisk slips 0.18% to $38.55

Highlights

Novo Nordisk completed the repurchase of 23,090,000 B shares, allocating DKK 10.56 billion since February 2026 under its buyback programme.
The current buyback authorization totals DKK 11.2 billion through February 1, 2027, reducing the outstanding share count by 37,849,179 B shares at an average price of DKK 278.97.
Shares of Novo Nordisk trade with short- and medium-term upside momentum, with price likely to consolidate between $37.74 and $39.36 barring a breakout above resistance.

Buyback progress supports capital return amid broader selling pressure

Novo Nordisk has completed the repurchase of 23,090,000 B shares under its current buyback programme, representing tangible progress in allocating capital to reduce the outstanding share count. Since the broader initiative began in February 2026, a total of 37,849,179 B shares have been bought back at an average price of DKK 278.97, with DKK 10.56 billion deployed toward these transactions. The program continues to authorize repurchases up to a limit of DKK 11.2 billion through February 1, 2027, though price action has remained under broader selling pressure.

Short-term bullish signals as longer-term trend remains unconfirmed

Turning to technical levels, NVO is trading above the MA-20 and MA-50 on the hourly chart, while remaining below the MA-200. On the indicator side, the Ichimoku Kijun is posted at $38.18 and provides immediate support. Both MACD and ADX are in Buy territory, while RSI stands at 60.28 and CCI is also signaling Buy. Bull/Bear Power indicates buyer dominance intraday. Stoch RSI and the Awesome Oscillator, however, remain Neutral and do not reinforce the prevailing momentum.

Upside scenario favored as price nears breakout resistance

Over the next several days, NVO is expected to trade within the $37.74 to $39.36 range based on typical volatility. A sideways consolidation is likely within this band, with the probability of an upward move ranked very high. A decisive breakout above $39.36 would open a path for further gains, while a drop below $37.74 could shift the focus back to downside risk.

Viktoras Karapetjanc, Traders Union analyst, sees Novo Nordisk’s ongoing share repurchase activity as a clear fundamental positive. He believes the company’s strong capital allocation underpins confidence, even as the stock faces short-term selling. Technical momentum remains constructive above key moving averages, and sentiment is bolstered by consistent buyback execution. "The combination of disciplined buybacks and underlying support levels positions NVO for further gains if $39.36 is cleared in the coming days."

Previously it was reported that Novo Nordisk views India as a strategic hub for clinical research and product development, supported by a robust R&D ecosystem and large patient base. With NVO's ongoing share repurchase programme and intraday technical strength, market participants should watch for a sustained close above $39.36 as a trigger for renewed upside momentum.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.